Table 1.

Human clinical trials in diabetes or diabetes related disease using senolytics or evaluating senescence

	Senolytics (S) or non-S	Target organs	Doses	Age, yr	Gender	Condition or disease	Identifier
Diabetes	D+Q	In vivo/kidney	(D 100 mg+Q 1,000 mg) 3 days	40–80	All	Chronic kidney disease	NCT02848131
	F	In vivo/kidney	(F 20 mg/kg/day) 2 consecutive days	40–80	All	Chronic kidney diseases, diabetes mellitusa, diabetic nephropathies	NCT03325322
	Bariatric surgery	Ex vivo/adipose tissue		18–60	All	Obesity, diabetes	NCT00476658
		Ex vivo/adipose tissue		18–65	All	Obesity, metabolic diseases, fibrosis, body weight	NCT01655017
		Ex vivo/adipose tissue		18–65	Female	Obesity, metabolic diseases, nutrition disorders, body weight	NCT01454232
	UBX1325	In vivo/eye	(UBX1325 50 μL) single intravitreal injection	≤18	All	Diabetic macular edema	NCT04857996
	UBX1325	In vivo/eye	(UBX1325) single dose	≤50	All	Diabetic macular edema, neovascular age-related macular degeneration	NCT04537884
Nondiabetes	NAC	In vivo/adipose tissue	Intervention: (NAC 600 mg/day) 4 weeks Control: (maltodextrin 600 mg/day) 4 weeks	≤25	All	Obese people with a BMI ≥30 kg/m2	IRCT20220727055563N1
	D+Q	In vivo/liver	(D 100 mg/day+Q 1,250 mg/day) 3 consecutive days, 3 consecutive weeks of dosing followed by a 4-week drug-free period, 3 cycles.	18–65	All	NAFLD, NASH with fibrosis, liver fibrosis	NCT05506488
	SGLT2i	In vivo/kidney	(Dapagliflozin 10 mg)	18–75	All	Chronic kidney disease (include DKD)	EUCTR2020-004835-26-IT
	D+Q or F	In vivo/skeletal muscle	(D 100 mg/day+Q 500 mg× 2/day) or (F 20 mg/kg/day)	≤18	All	Frailty, childhood cancer	NCT04733534

World Health Organization International Clinical Trials Registry Platform Search Portal. MeSH 79 records for 65 trials found for: senescence OR senescent OR senolytics OR senolysis OR senomorphic OR senotherapy OR senotherapeutic. Clinical studies or observational studies targeting diabetes or diabetes related pathologies and using senolytic to see at senescence have been selected and listed.

D+Q, dasatinib and quercetin; F, fisetin; NAC, N-Acetylcystein; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SGLT2i, sodium-glucose cotransporter 2 inhibitor; DKD, diabetic kidney disease.

^aFor the DKD subgroup: diabetes mellitus (on medication).